LEO Pharma has reported topline outcomes from the Phase IIb trial of temtokibart, a potential new treatment for atopic ...

NMIBC is becoming more prominent as its incidence is correlated with older age groups, with the median age being 70 when ...

The Danish multinational said that Sogroya improved the yearly growth rate in pre-pubertal children born small for ...

Vir is holding off on advancing the combination therapy to Phase III trials in hepatitis B until it secures a development ...

Johnson & Johnson (J&J) has reported new data from the Phase III ICONIC-TOTAL trial, assessing icotrokinra in treating plaque ...

A panel at OCT Europe touched upon where the European clinical trial industry is headed and the impact of technology and ...

GSK has reported positive outcomes from the Phase III GLISTEN trial of linerixibat for cholestatic pruritus (itch) and PBC.

AstraZeneca and Daiichi's Enhertu, followed by THP, has shown pCR rate improvement in the randomised DESTINY-Breast11 Phase ...

Cognition Therapeutics has announced positive topline outcomes from the Phase II MAGNIFY trial of zervimesine in adult ...

Boehringer Ingelheim has begun the JADE Phase II trial to evaluate BI 1584862 as a first-in-class oral treatment for ...

AbolerIS Pharma has dosed the Phase I study’s first cohort subjects with ABO21009, aimed at treating rheumatoid arthritis (RA ...

The US Food and Drug Administration (FDA) has set an "aggressive" timeline to implement genAI across the agency by 30 June ...